Immune biologics including TNF-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s lucrative biologic Humira (adalimumab), which are available in Europe in October 2018, and biosimilars referencing Roche’s Rituxan/MabThera, which have already launched in Europe and are set to launch in the United States in Q3 2019. As the immune biosimilars space becomes increasingly competitive, it is important that manufacturers/marketers of biosimilars and branded biologics understand which factors influence physicians’ uptake. Decision Resources Group has conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians’ attitudes toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.
Key companies mentioned:
Key drugs mentioned: